 Axogen, Inc. AXGN, a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced a financing agreement with Oberland Capital and provided preliminary, estimated revenue for the second quarter ended June 30, 2020. We are pleased to announce this new debt facility with Oberland Capital, noted Peter J. Mariani, chief financial officer of Axogen. I am very pleased with the Axogen teams commitment to our customers and the support we have provided as surgical schedules reopened during the quarter, commented Karen Zaderej, chairman, CEO, and president of Axogen. 